Q3 EPS Estimates for Aspen Aerogels Cut by Roth Capital

Aspen Aerogels, Inc. (NYSE:ASPN) – Investment analysts at Roth Capital cut their Q3 2024 earnings per share (EPS) estimates for shares of Aspen Aerogels in a report issued on Thursday, October 17th. Roth Capital analyst C. Moore now expects that the construction company will post earnings of ($0.16) per share for the quarter, down from their prior estimate of ($0.04). The consensus estimate for Aspen Aerogels’ current full-year earnings is $0.21 per share. Roth Capital also issued estimates for Aspen Aerogels’ FY2024 earnings at ($0.02) EPS and Q4 2025 earnings at $0.25 EPS.

Aspen Aerogels (NYSE:ASPN) last issued its earnings results on Wednesday, August 7th. The construction company reported $0.21 earnings per share for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. Aspen Aerogels had a net margin of 0.39% and a return on equity of 0.74%. The company had revenue of $117.80 million for the quarter, compared to analysts’ expectations of $101.99 million. During the same period in the prior year, the company earned ($0.22) earnings per share. The firm’s revenue was up 144.4% compared to the same quarter last year.

Other analysts have also recently issued reports about the company. TD Cowen increased their price target on Aspen Aerogels from $36.00 to $41.00 and gave the stock a “buy” rating in a research report on Tuesday, August 20th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Aspen Aerogels in a research note on Wednesday, October 16th. Barclays started coverage on Aspen Aerogels in a research note on Tuesday, August 6th. They issued an “overweight” rating and a $27.00 target price on the stock. Benchmark reissued a “buy” rating and set a $14.00 price target on shares of Aspen Aerogels in a report on Thursday, August 8th. Finally, Roth Mkm reaffirmed a “buy” rating and issued a $36.00 price objective on shares of Aspen Aerogels in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.70.

Aspen Aerogels Price Performance

ASPN opened at $21.33 on Monday. The company has a quick ratio of 2.82, a current ratio of 3.46 and a debt-to-equity ratio of 0.23. The company’s 50-day moving average price is $25.96 and its 200 day moving average price is $24.48. Aspen Aerogels has a fifty-two week low of $6.62 and a fifty-two week high of $33.15. The firm has a market cap of $1.62 billion, a price-to-earnings ratio of -48.48 and a beta of 2.16.

Insiders Place Their Bets

In other Aspen Aerogels news, CFO Ricardo C. Rodriguez sold 32,465 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $30.14, for a total value of $978,495.10. Following the completion of the sale, the chief financial officer now directly owns 20,790 shares in the company, valued at $626,610.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Aspen Aerogels news, CEO Donald R. Young sold 63,355 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $30.03, for a total value of $1,902,550.65. Following the completion of the sale, the chief executive officer now directly owns 483,640 shares of the company’s stock, valued at approximately $14,523,709.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Ricardo C. Rodriguez sold 32,465 shares of Aspen Aerogels stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $30.14, for a total transaction of $978,495.10. Following the completion of the transaction, the chief financial officer now directly owns 20,790 shares in the company, valued at $626,610.60. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.30% of the stock is owned by insiders.

Institutional Trading of Aspen Aerogels

Several institutional investors and hedge funds have recently added to or reduced their stakes in ASPN. Banque Cantonale Vaudoise lifted its holdings in shares of Aspen Aerogels by 37.5% during the first quarter. Banque Cantonale Vaudoise now owns 4,593 shares of the construction company’s stock valued at $81,000 after purchasing an additional 1,252 shares during the last quarter. Point72 Hong Kong Ltd purchased a new position in Aspen Aerogels in the 2nd quarter worth about $84,000. nVerses Capital LLC acquired a new stake in Aspen Aerogels during the 2nd quarter worth about $95,000. Quent Capital LLC purchased a new stake in Aspen Aerogels during the third quarter valued at about $118,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Aspen Aerogels in the second quarter worth about $121,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Aspen Aerogels

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.